PetVivo Holdings Announces Digital Landia's Publication of Technical Whitepaper Validating AgenticPet AI Framework Under Exclusive 10-Year Licensing Agreement
MWN-AI** Summary
PetVivo Holdings, Inc. (OTCQX: PETV) announced an important development regarding its collaboration with Digital Landia Holding Corp. The companies have disclosed a technical whitepaper validating the AgenticPet AI Framework, which is the backbone of PetVivo's upcoming B2B veterinary platform set to launch in the first quarter of 2026. This announcement follows a comprehensive October 2025 licensing agreement that allows PetVivo to leverage Digital Landia's AI technology for the next decade.
The whitepaper outlines the framework's robust architecture designed specifically for modern veterinary practices, showcasing capabilities that can cut client acquisition costs by 90% to 98%, along with offering universal diagnostic assistance through its specialized AI agents. Additionally, the framework aligns with Gen Z’s expectations through enhanced mobile access, reflecting the growing pet ownership trend among younger demographics.
Key innovations highlighted in the whitepaper include five patent-pending technologies that offer PetVivo competitive advantages, such as adaptive learning pipelines and privacy-preserving data synthesis. The enterprise-grade architecture emphasizes security and integration, ensuring compliance with regulations like HIPAA.
PetVivo’s existing distribution network, bolstered by partnerships with organizations like Veterinary Growth Partners, positions the company well for the rapid deployment of the AgenticPet platform. The licensing structure emphasizes the potential for diversified revenue streams and platform network effects, which will further augment value as adoption increases.
Overall, this strategic partnership with Digital Landia signifies a crucial step in PetVivo’s strategy to modernize veterinary care and offers significant promise as the company prepares for its dual-platform launch in early 2026. The full technical documentation is accessible online for stakeholders interested in examining the framework's capabilities.
MWN-AI** Analysis
PetVivo Holdings (OTCQX: PETV; OTCID: PETVW) has made a significant announcement that could bolster its position in the veterinary technology market. The publication of the technical whitepaper for the AgenticPet AI Framework, developed in collaboration with Digital Landia, validates the company's commitment to integrating cutting-edge technology in its veterinary platform set to launch in Q1 2026. This development offers several key takeaways for investors and stakeholders.
Firstly, the exclusive 10-year licensing agreement showcases PetVivo’s long-term vision. By offering innovative AI solutions tailored for veterinary practices, PetVivo is positioning itself to capitalize on the growing demand for digital transformation within the industry. The AgenticPet framework promises substantial reductions in client acquisition costs and improved diagnostic assistance, creating value for veterinary professionals—an attractive proposition during a time of rising operational costs.
Additionally, the outlined technical benefits, such as HIPAA-aligned privacy measures and robust data integration capabilities, indicate that the platform is aligned with current regulatory expectations and industry standards, enhancing its appeal. Investors should view this as a competitive advantage in an increasingly saturated market.
The strategic distribution partnership with Veterinary Growth Partners, providing access to over 7,300 veterinary professionals, further establishes a strong foundation for large-scale deployment upon the platform's launch. This network not only facilitates immediate user engagement but could also foster a strong word-of-mouth effect as early adopters share their experiences.
The impending dual-platform launch in 2026 and the anticipated increase in pet ownership among Gen Z consumers underscore significant growth potential. The demographic insights suggest that as more young pet owners enter the market, PetVivo's offerings may see accelerated uptake.
In summary, PetVivo Holdings appears well-positioned for future growth in the veterinary sector. Investors should monitor the upcoming launch and consider the company's innovative technology framework, strategic partnerships, and the favorable demographic trends when assessing market opportunities.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Comprehensive Documentation Confirms Production-Ready Architecture for PetVivo’s Veterinary Platform Launching Q1 2026
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced that its exclusive AI technology partner, Digital Landia Holding Corp., has published a comprehensive technical whitepaper documenting the AgenticPet AI Framework powering PetVivo's B2B veterinary-practice platform.
The whitepaper validates the technical foundation underlying PetVivo's October 2025 exclusive 10-year white-label licensing agreement, providing veterinary professionals, investors, and industry stakeholders with detailed visibility into the multi-agent artificial intelligence architecture that enables transformative clinical and economic benefits for veterinary practices.
TECHNICAL DUE DILIGENCE VALIDATED
"Our October announcement represented months of rigorous technical due diligence," stated John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "We don't partner lightly—especially on decade-long agreements. Today's whitepaper demonstrates exactly what we evaluated: a production-ready AI framework with genuine clinical utility, protected intellectual property, and enterprise-grade architecture capable of serving our entire veterinary network. This isn't a proof of concept; it's fully deployable infrastructure."
FRAMEWORK CAPABILITIES ALIGNED WITH VETERINARY NEEDS
The published whitepaper details technical capabilities that directly address modern veterinary practice challenges, including a 90 to 98 percent reduction in client acquisition costs through seamless pet-parent data flows; universal diagnostic assistance with nine specialized AI agents available across entire clinic patient bases; and enhanced Gen Z market access through a mobile-first consumer experience aligned with digital-native expectations.
INTELLECTUAL PROPERTY PROTECTION
The whitepaper reveals five patent-pending innovations protecting the AgenticPet framework’s core functionality, providing PetVivo with significant competitive advantages under its exclusive 10-year licensing agreement: (1) distributed agent-certification systems; (2) swarm-intelligence coordination protocols; (3) privacy-preserving health-data synthesis; (4) real-time veterinary-integration layers; and (5) adaptive learning pipelines.
ENTERPRISE-READY ARCHITECTURE
The technical documentation demonstrates an architecture specifically designed for professional veterinary-practice requirements, including end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy frameworks, API specifications for practice-management-system integration, automated health-history uploads, and cloud-native infrastructure ensuring over 99.9 percent uptime reliability.
"The whitepaper makes clear that Digital Landia built this framework for veterinarians—not just pet parents," noted Mr. Lai. "The enterprise-grade security, seamless integration specifications, and clinical workflow design demonstrate a deep understanding of veterinary practice operations."
DISTRIBUTION NETWORK READY
PetVivo's established product distribution network, including its partnership with Veterinary Growth Partners (VGP), a prominent veterinary association that has more than 7,300 veterinary professional members, and its established relationships with over 1,000 clinics already using its existing SPRYNG ® and PrecisePRP ™ product lines, positions the Company to rapidly deploy the AgenticPet platform across a rapidly expanding veterinary industry.
STRATEGIC RATIONALE FOR EXCLUSIVE AGREEMENT
PetVivo's exclusive 10-year licensing structure reflects its confidence in the framework’s competitive positioning and multiple revenue streams, including B2B subscriptions, lead-generation fees, and premium features. Platform network effects increase value as adoption grows, supported by strong demographic tailwinds as Gen Z pet ownership rises approximately 43.5 percent annually.
PARTNERSHIP MILESTONE PROGRESSION
Today's publication marks the third major milestone in the PetVivo–Digital Landia partnership: (1) the March 2025 strategic alliance announcement; (2) the October 2025 exclusive 10-year licensing agreement; and (3) the November 2025 comprehensive technical whitepaper enabling independent evaluation of the framework.
Q1 2026 DUAL-PLATFORM LAUNCH
The documented technical foundation supports a Q1 2026 commercial launch featuring Digital Landia's B2C AgenticPet app and PetVivo's B2B veterinary platform with white-labeled AI diagnostic assistance. Pre-launch registration opens in January 2026 .
WHITEPAPER ACCESS
The AgenticPet AI Framework Technical Whitepaper is publicly available at: https://digital-landia.gitbook.io/agentic-pet-whitepaper/ .
PetVivo encourages veterinary professionals, investors, and industry stakeholders to review this comprehensive technical documentation.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG ® with OsteoCushion ® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP ® , a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ**
How does the comprehensive documentation of the AgenticPet AI Framework impact the perceived value of PetVivo Holdings Inc. Warrant PETVW in relation to the upcoming veterinary platform launch?
Given the rigorous technical due diligence outlined, what specific competitive advantages does PetVivo Holdings Inc. Warrant PETVW hold in the rapidly expanding veterinary market?
How does the partnership with Digital Landia enhance the strategic value of PetVivo Holdings Inc. Warrant PETVW, especially in light of the upcoming Q1 2026 launch?
What revenue streams generated by the AgenticPet platform could positively influence the market outlook for PetVivo Holdings Inc. Warrant PETVW as it approaches its commercial launch?
**MWN-AI FAQ is based on asking OpenAI questions about PetVivo Holdings Inc. Warrant (OTC: PETVW).
NASDAQ: PETVW
PETVW Trading
0.07% G/L:
$0.0344 Last:
5,000 Volume:
$0.034375 Open:
